Outlook TherapeuticsOTLK
OTLK
$7.95
1.66%
Market Cap: $188M
About: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Employees: 24
0
Funds holding %
of 6,686 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
14% more funds holding
Funds holding: 56 [Q1] → 64 (+8) [Q2]
21.86% less ownership
Funds ownership: 58.14% [Q1] → 36.28% (-21.86%) [Q2]
30% less capital invested
Capital invested by funds: $90.1M [Q1] → $62.7M (-$27.4M) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 0 (-2) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
277%
upside
Avg. target
$39
386%
upside
High target
$53
567%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo 25% 1-year accuracy 10 / 40 met price target | 315%upside $33 | Buy Maintained | 3 Sept 2024 |
Chardan Capital Daniil Gataulin 18% 1-year accuracy 3 / 17 met price target | 567%upside $53 | Buy Maintained | 16 Aug 2024 |
HC Wainwright & Co. Douglas Tsao 50% 1-year accuracy 70 / 139 met price target | 277%upside $30 | Buy Reiterated | 15 Aug 2024 |
Financial journalist opinion
Based on 6 articles about OTLK published over the past 30 days